Business Description
Mesoblast Ltd
NAICS : 541711
ISIN : AU000000MSB8
Share Class Description:
FRA:LWB: Ordinary SharesCompare
Compare
Traded in other countries / regions
MSB.AustraliaMESO.USALWB.Germany IPO Date
2006-01-26Description
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.63 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -2.52 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.76 | |||||
| Beneish M-Score | -2.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -44.5 | |||||
| 3-Year EBITDA Growth Rate | 14.5 | |||||
| 3-Year EPS without NRI Growth Rate | 6.9 | |||||
| 3-Year FCF Growth Rate | 3.8 | |||||
| 3-Year Book Growth Rate | -12.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.11 | |||||
| 9-Day RSI | 71.61 | |||||
| 14-Day RSI | 70.79 | |||||
| 6-1 Month Momentum % | 36.67 | |||||
| 12-1 Month Momentum % | -49.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.71 | |||||
| Quick Ratio | 2.71 | |||||
| Cash Ratio | 2.46 | |||||
| Days Sales Outstanding | 120.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.9 | |||||
| Shareholder Yield % | -7.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -877.49 | |||||
| Net Margin % | -1072.57 | |||||
| FCF Margin % | -774.85 | |||||
| ROE % | -13.03 | |||||
| ROA % | -9.77 | |||||
| ROIC % | -8.62 | |||||
| ROC (Joel Greenblatt) % | -754.69 | |||||
| ROCE % | -8.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 0.12 | |||||
| PE Ratio without NRI | 0.12 | |||||
| PEG Ratio | 0.01 | |||||
| PS Ratio | 76.25 | |||||
| PB Ratio | 1.22 | |||||
| EV-to-EBIT | -14.76 | |||||
| EV-to-EBITDA | -15.67 | |||||
| EV-to-Revenue | 125.38 | |||||
| EV-to-Forward-Revenue | 17.13 | |||||
| EV-to-FCF | -15.64 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | -6.78 | |||||
| FCF Yield % | -6.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mesoblast Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5.654 | ||
| EPS (TTM) (€) | 4.888 | ||
| Beta | 3.3 | ||
| Volatility % | 188.29 | ||
| 14-Day RSI | 70.79 | ||
| 14-Day ATR (€) | 0.023992 | ||
| 20-Day SMA (€) | 0.5011 | ||
| 12-1 Month Momentum % | -49.84 | ||
| 52-Week Range (€) | 0.134 - 0.830482 | ||
| Shares Outstanding (Mil) | 1,140.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mesoblast Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mesoblast Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mesoblast Ltd Frequently Asked Questions
What is Mesoblast Ltd(FRA:LWB)'s stock price today?
The current price of FRA:LWB is €0.55. The 52 week high of FRA:LWB is €0.83 and 52 week low is €0.13.
When is next earnings date of Mesoblast Ltd(FRA:LWB)?
The next earnings date of Mesoblast Ltd(FRA:LWB) is 2024-05-24 Est..
Does Mesoblast Ltd(FRA:LWB) pay dividends? If so, how much?
Mesoblast Ltd(FRA:LWB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers